A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.
作者信息
Brandwein J M, Yang L, Schimmer A D, Schuh A C, Gupta V, Wells R A, Alibhai S M H, Xu W, Minden M D
出版信息
Leukemia. 2007 Apr;21(4):821-4. doi: 10.1038/sj.leu.2404545. Epub 2007 Jan 25.